Thylacine Biotherapeutics Licenses Novel Antiviral Peptide Platform from Columbia University
/PRNewswire/ -- Thylacine Biotherapeutics Inc. ("Thylacine Bio"), a privately held biotech company dedicated to combating infectious disease, announced today...
Source: prnewswire.com